Price
$0.55+0.58%Social Signal Score
Analyst Ratings
3 analystsRevenue
$27.18M+27085.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steven Lo
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 65
- Beta
- 1.06
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -0.59
Financials
Revenue
$27.18M+27085.0%Net Income
$-13.49MEBITDA
$-12.19MFree Cash Flow
$2.74MEPS (diluted)
$-0.06Shares Outstanding (diluted)
242.17M+589.4%Operating Expenses
$40.36MCash & Debt
$63.98MReturn of Capital
$0.00Revenue by Segment (annual)
$250.13MDividend per Share
$12.19Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $237.26M | $16.33M | $0.07 |
| 2024 | $28.70M | $-66.95M | $-0.14 |
| 2023 | $7.38M | $-82.47M | $-0.17 |
| 2022 | $107.0K | $-107.76M | $-0.22 |
| 2021 | $892.0K | $-70.47M | $-0.14 |
| 2020 | $4.05M | $-32.22M | $-0.07 |
| 2019 | $9.86M | $-18.64M | $-0.09 |
| 2018 | $4.16M | $-18.01M | $-0.29 |
| 2017 | $5.84M | $-12.46M | $-0.33 |
| 2016 | $8.90M | $-29.40M | $-0.84 |
| 2015 | $9.30M | $-25.40M | $-0.72 |
| 2014 | $24.60M | $-19.10M | $-0.59 |
| 2013 | $68.70M | $-11.00M | $-0.39 |
| 2012 | $33.60M | $-8.90M | $-0.35 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.10
- Implied price
- $0.52
- Return from $0.44
- 3.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.26 — -40.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 1 | 3 | 5 | 7 | 9 |
|---|---|---|---|---|---|
| -2.0% | -31.9% | -15.1% | -6.0% | 0.5% | 5.7% |
| 3.0% | -28.4% | -10.8% | -1.2% | 5.7% | 11.1% |
| 8.0% | -24.9% | -6.5% | 3.6% | 10.8% | 16.5% |
| 13.0% | -21.5% | -2.2% | 8.4% | 15.9% | 21.9% |
| 18.0% | -18.0% | 2.2% | 13.2% | 21.0% | 27.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (5)
- Newsmarketbeat.com·21d ago·Neutral
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference Vaxart OTCMKTS: VXRT Chief Executive Officer Steve Lo outlined the company's oral vaccine platform, its government-funded COVID-19 study and development opportunities in norovirus and influenza during an H.C. Wainwright conference presentation.
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that a member of its management team will present at the H.C.
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European markets European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European markets
View source ↗ - Newsmarketbeat.com·57d ago·Neutral
Vaxart Q2 Earnings Call Highlights Vaxart OTCMKTS: VXRT said it has reported positive 12-month safety data from the 400-participant Sentinel cohort of its Phase II-B COVID-19 vaccine trial and remains on track to disclose top-line data from the larger, approximately 5,000-participant main cohort in the first half of 2027.
View source ↗ - Newsseekingalpha.com·59d ago·Positive
Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.31 per share
Typical surprise +22.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.06 vs $-0.12beat
- Thu, May 7$0.02 vs $0.02beat
- Thu, Mar 12$-0.11 vs $-0.05miss
- Thu, Nov 13$-0.04 vs $-0.07beat
- Wed, Aug 13$-0.07 vs $-0.09beat
- Tue, May 13$-0.07 vs $-0.07beat
Estimates and results for VXRT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VXRT officers and directors.
- Bought
- $159k
- Sold
- —
14 trades
0 trades
- Watson W. Markbought
- Watson W. Markbought
- Watson W. Markbought
- Heron Elaine Jbought
- Heron Elaine Jbought
- Finney Kevinbought
- Finney Kevinbought
- Finney Kevinbought
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VXRT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.